摘要
目的基于国内经济水平及医疗现状,对动脉粥样硬化性心脏病(ASCVD)患者使用英克司兰注射液进行经济学评价。方法从中国卫生体系角度研究,采用马尔科夫(Markov)模型,将ASCVD患者分为英克司兰注射液组和安慰剂组,2组均采用常规降脂药物治疗,研究时限25年。率值参数、成本参数和效果参数源于ORION-18试验及其他文献资料。效果以质量调整生命年(QALYs)表示。以增量成本-效果比(ICER)评价英克司兰注射液经济性,分析单因素敏感性和概率敏感性,验证结果可靠性。结果英克司兰注射液组治疗效果更高(10.02QALYs),安慰剂组成本更低(255179元)。2组比较,ICER值为137850元·QALY^(-1),以2022年3倍我国人均国民生产总值(GDP)(257094元)为阈值,英克司兰注射液具有一定经济学优势,敏感性分析支持该结果。结论在3倍我国人均GDP阈值下,英克司兰注射液治疗ASCVD具有经济学优势。
Objective To evaluate the cost-effectiveness of inclisiran injection treatment in patients with atherosclerotic heart disease(ASCVD)in China.Methods From the perspective of China's health system,according to the Markov model,patients with ASCVD were divided into inclisilan injection group and placebo group,and both groups were treated with conventional lipid-lowering drugs.The study period was 25 years.The rate parameters,cost parameters,and effectiveness parameters were derived from the ORION-18 trial and other literature.Effects were expressed as quality-adjusted life-years(QALYs).The incremental cost-effectiveness ratio(ICER)was used to evaluate the economy of inclisilan injection.One-way sensitivity analysis and probability sensitivity analysis were used to verify the reliability of the results.Results The treatment effect of the inclisilan injection group was higher(10.02 QALYs),and the cost of the placebo group was lower(255179 yuan).The ICER of the two groups was 137850 yuan per QALY gained,and using 257094 yuan per capita by 2022 as the threshold,the treatment would be economically advantageous.Sensitivity analysis supported this result.Conclusion At present,the additional use of inclisilan injection can get a better treatment effect,and it has economic advantages under the threshold of three times GDP per capita in China.
作者
冯冰
高宁
高胜男
牛梦娜
郭珊
刘国强
FENG Bing;GAO Ning;GAO Shengnan;NIU Mengna;GUO Shan;LIU Guoqiang(Department of Clinical Pharmacy,Hebei Medical University Third Hospital,Shijiazhuang 050051,China;Hebei Society for Integrated Drug and Health Technology Assessment,Shijiazhuang 050051,China)
出处
《医药导报》
北大核心
2025年第3期466-472,共7页
Herald of Medicine
基金
河北省自然科学基金资助项目(H202120-6407)。
作者简介
冯冰(1999-),男,回族,河北沧州人,在读硕士,研究方向:临床药学。ORCID:0009-0008-2238-2421,电话:0311-88603319,E-mail:banlaliulian@163.com;通信作者:刘国强(1967-),男,河北石家庄人,主任药师,硕士生导师,研究方向:药物经济学、临床药学。电话:0311-88603319,E-mail:liugq1223@sohu.com。
